X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (643) 643
Publication (53) 53
Conference Proceeding (38) 38
Patent (30) 30
Book Chapter (11) 11
Book / eBook (8) 8
Web Resource (8) 8
Book Review (6) 6
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (356) 356
humans (351) 351
female (325) 325
breast cancer (248) 248
breast neoplasms - drug therapy (228) 228
index medicus (222) 222
middle aged (159) 159
breast neoplasms - pathology (149) 149
chemotherapy (131) 131
aged (123) 123
cancer (119) 119
adult (118) 118
trastuzumab (108) 108
prognosis (104) 104
breast neoplasms - genetics (97) 97
treatment outcome (95) 95
chemotherapy, adjuvant (94) 94
antineoplastic agents - therapeutic use (92) 92
disease-free survival (85) 85
antineoplastic combined chemotherapy protocols - therapeutic use (84) 84
therapy (68) 68
breast neoplasms - mortality (65) 65
breast neoplasms - metabolism (62) 62
clinical trials (62) 62
care and treatment (61) 61
research (60) 60
hematology, oncology and palliative medicine (59) 59
adjuvant chemotherapy (57) 57
tumors (57) 57
drug therapy (54) 54
receptor, erbb-2 - metabolism (54) 54
survival (54) 54
metastasis (48) 48
neoplasm staging (46) 46
gene expression (44) 44
postmenopausal women (44) 44
gene expression profiling (41) 41
antibodies, monoclonal, humanized (39) 39
survival analysis (38) 38
tamoxifen (38) 38
analysis (37) 37
breast neoplasms - chemistry (37) 37
paclitaxel (37) 37
breast neoplasms - therapy (36) 36
medicine & public health (36) 36
lapatinib (35) 35
patients (35) 35
women (35) 35
clinical trials as topic (34) 34
docetaxel (34) 34
randomized controlled trials as topic (34) 34
cancer therapies (33) 33
antineoplastic combined chemotherapy protocols - adverse effects (32) 32
drug administration schedule (32) 32
receptor, erbb-2 - analysis (32) 32
adjuvant treatment (31) 31
aged, 80 and over (31) 31
antibodies, monoclonal - therapeutic use (31) 31
antineoplastic agents - adverse effects (31) 31
endocrine therapy (31) 31
risk factors (31) 31
open-label (30) 30
receptors, estrogen - metabolism (30) 30
antineoplastic agents - administration & dosage (29) 29
biomarkers, tumor - analysis (29) 29
breast (29) 29
estrogen (29) 29
receptor, erbb-2 - genetics (29) 29
follow-up studies (28) 28
health aspects (28) 28
her2 (28) 28
immunohistochemistry (28) 28
medicine (28) 28
randomized-trial (28) 28
time factors (28) 28
antineoplastic agents (27) 27
cells (27) 27
expression (27) 27
genetic aspects (27) 27
receptor, erbb-2 - antagonists & inhibitors (27) 27
surgery (27) 27
tamoxifen - therapeutic use (27) 27
biomarkers, tumor - genetics (26) 26
doxorubicin (26) 26
neoplasm metastasis (26) 26
survival rate (26) 26
oligonucleotide array sequence analysis (25) 25
oncology, experimental (25) 25
receptors, estrogen - analysis (25) 25
research article (25) 25
trial (25) 25
antimitotic agents (24) 24
antineoplastic agents, hormonal - therapeutic use (24) 24
neoadjuvant therapy (24) 24
predictive value of tests (24) 24
biomarkers (23) 23
breast neoplasms - diagnosis (23) 23
erbb-2 protein (23) 23
medical research (23) 23
paclitaxel - administration & dosage (23) 23
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (694) 694
French (18) 18
German (5) 5
Chinese (2) 2
Spanish (2) 2
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


EUROPEAN JOURNAL OF CANCER, ISSN 0959-8049, 02/2001, Volume 37, Issue 3, pp. 295 - 295
Journal Article
2009, 1. Aufl., Cancer treatment and research, ISBN 0387751149, Volume 151, xvi, 490
Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for... 
Breast | Adjuvant treatment | Cancer | Treatment | Oncology | Cancer Research | Medicine & Public Health | Surgical Oncology
Book
Nature Reviews Cancer, ISSN 1474-175X, 07/2007, Volume 7, Issue 7, pp. 545 - 553
The advent of microarray technology has enabled scientists to simultaneously investigate the expression of thousands of genes. Gene-expression profiling... 
Breast Neoplasms - classification | Neoplasms - therapy | Algorithms | Breast Neoplasms - genetics | Prognosis | Neoplasms - genetics | Oligonucleotide Array Sequence Analysis | Humans | Female | Gene Expression Profiling | Decision Trees | Care and treatment | Usage | DNA microarrays | Breast cancer | Genetic aspects | Diagnosis | Gene expression | Health aspects
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9938, pp. 164 - 172
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Medical research | Ligands | Cytotoxicity | Mammography | Kinases | Cancer therapies | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Surgery | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | Diarrhea | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9897, pp. 1021 - 1028
Journal Article